If you have been running a growth hormone secretagogue for fat loss and the results stalled, the instinct is almost always the same. Blame the compound. Switch from CJC 1295 without DAC to Tesamorelin, or the other direction. Add something to the stack. Bump the dose. And the result stays flat, because the thing that actually controls how much fat you burn from these peptides is a single number that switching compounds cannot change.

This post breaks down what that number is, why CJC 1295 and Tesamorelin produce the exact same version of it, the three variables that actually move it, and the questions researchers ask most about these two compounds. It is the written companion to the full video, which is embedded below, and it goes a layer deeper than the video does on timing, expectations, and the common questions.

The amount of fat your body releases and burns from a growth hormone secretagogue comes down to one number. How high the growth hormone pulse climbs after each injection. That is pulse height, and it is the variable that decides your result.

Pulse height is not controlled by which GHRH analog you choose. GHRH stands for growth hormone releasing hormone, the natural signal your body uses to ask the pituitary gland for growth hormone. Tesamorelin is a GHRH analog. CJC 1295 without DAC is a GHRH analog. Both copy the exact same signal, and both bind the exact same receptor.

Both compounds are what is called a full agonist. A full agonist switches a receptor on as far as it will go. Picture a dimmer switch on a single light. Tesamorelin turns the dimmer all the way up. CJC 1295 without DAC also turns it all the way up. Two different switches, same bulb, same brightness. You cannot make the bulb brighter by wiring in a different switch.

The reason that ceiling is real comes down to receptor saturation. Every receptor has a point where every available binding site is filled. Past that point there is nothing left to activate. More signal does not produce more response, because the receptor has nowhere left to go. At a comparable dose, both Tesamorelin and CJC 1295 without DAC are already at that point. Research does not suggest one produces a taller pulse than the other.

So the search for a stronger GHRH analog is a search for something that does not exist in this category. The fat loss signal comes from pulse height, the pulse height is capped at the receptor, and the receptor ceiling is the same for both compounds.

If the compound does not raise your pulse, something does. Three things set how high your pulse actually climbs, and not one of them is which GHRH analog is in the syringe.

Lever one: the GHRP you pair it with

A GHRP is the second peptide in the stack, something like Ipamorelin. The GHRH analog loads the signal. The GHRP fires it. And the GHRP side is where the peak can actually move, because it works through a completely different receptor and a completely different mechanism. This is the side of the stack worth evaluating when the pulse needs to climb higher.

Lever two: insulin and the fed state

When you eat, insulin rises, and insulin directly suppresses the GH pulse you are trying to build. It does not soften it slightly. It flattens it. An injection that happens in a fed state, meaning after a meal, after a protein shake, after anything that pushed insulin up, is an injection that already capped its own pulse before the compound ever got a chance. This is one of the most common reasons fat loss stalls on a GH secretagogue protocol, and it almost never gets identified, because nobody connects the injection timing to what they ate two hours before.

Lever three: the injection window

Your body is not equally receptive to a GH pulse at every hour of the day. It has its own rhythm, and there are windows where the pituitary is primed and willing to fire a strong pulse, and windows where it is resistant. Hitting a receptive window versus a closed one changes how high the pulse actually climbs from the same compound at the same dose. Most researchers inject at whatever time is convenient, and convenient and optimal are rarely the same window.

Get those three wrong and the compound does not matter. You have capped your own pulse below what the receptor could have produced, and no compound switch fixes that.

The video keeps the timing lever deliberately simple. Here is the layer underneath it. Growth hormone is released in pulses across the day and night, and the largest natural pulse happens during deep sleep. Insulin and food are the two things that most reliably blunt a pulse, so the practical goal is to inject when insulin is low and the body is not already fighting you.

In practice that points to two windows most researchers can actually use. The first is fasted in the morning before eating, when insulin is at its lowest after the overnight fast. The second is before sleep, at least a couple of hours after the last meal, so food is cleared and insulin has come back down. The exact window depends on your schedule and your last meal, which is the entire point. The clock time matters less than the state you are in when you inject. Low insulin, empty stomach, and a body that is ready to fire.

The mistake is treating timing as a fixed hour on a calendar. It is not a time, it is a condition. An injection at the perfect hour on a full stomach is worse than an injection at an average hour fully fasted, because insulin overrides the clock.

This is one of the most searched questions on both compounds, and the honest answer is that a GH secretagogue is not a fast visual change the way a strong appetite suppressant can be. It works by raising growth hormone, which drives fat mobilization gradually, so the timeline is measured in weeks and months, not days.

In the first two to four weeks, most of what changes is not visible on the scale. Sleep quality and recovery often shift first, because growth hormone influences both. Visible fat change, especially stubborn visceral belly fat, is a slower process that builds over a longer run, which is exactly why the four week mark is where so many researchers wrongly decide the compound failed and switch. If the pulse is landing and the three levers are in place, the direction over eight to twelve weeks is what matters, not the first month.

The trap here is judging the compound at four weeks by feel. There is no way to feel pulse height, so a slow first month gets misread as a broken protocol, and the researcher switches compounds instead of checking whether the pulse was ever landing. That is the same mistake the whole video is built around.

FOR EDUCATIONAL AND RESEARCH PURPOSES ONLY. NOT MEDICAL ADVICE. NOT FOR HUMAN USE GUIDANCE.